Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

References

• Global Initiative for Chronic Obstructive Lung DGlobal Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed February 25, 2013
   Google Scholar
• National Institute for Health and Clinical ExcellenceChronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update)National Institute for Health and Care Excellence2013 [updated May 8, 2013] Available from: http://guidance.nice.org.uk/cg101Accessed May 13, 2013
   Google Scholar
• United States Food and Drug AdministrationPrescribing Information: TUDORZA PRESSAIR Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdfAccessed February 25, 2013
   Google Scholar
• Boehringer Ingelheim Limited [homepage on the Internet]Summary of product characteristics: Spiriva® Respimat® 2.5 microgram, Solution for InhalationBoehringer Ingelheim Limited [updated June 27, 2013. Available from: http://www.medicines.org.uk/emc/medicine/20134Accessed July 2, 2013
   Google Scholar
• European Medicines AgencySummary of Product Characteristics: Eklira Genuair 322 micrograms inhalation powder Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdfAccessed February 25, 2013
   Google Scholar
• United States Food and Drug AdministrationHighlights of Prescribing Information for TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder)2012St Louis, MO, USAForest Pharmaceuticals Inc Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdfAccessed February 25, 2013
   Google Scholar
• van der PalenJGinkoTKrokerAPreference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD [abstract]Eur Respir J201240Suppl 56389s
   Google Scholar
• European Medicines AgencySummary of Opinion: Glycopyrronium BromideLondonEuropean Medicines Agency2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002691/WC500129032.pdfAccessed February 25, 2013
   Google Scholar
• BeierJKirstenAMMrozRS51 Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: A phase IIIb studyThorax201267Suppl 2A26A27
   Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceThe Guidelines Manual 2009. Appendix D: Methodology Checklist: Randomised Controlled TrialsLondonNational Institute for Health and Care Excellence2009 Available from: http://www.nice.org.uk/media/633/21/The_guidelines_manual_2009_-_Appendix_D_Methodology_checklist_-_randomised_controlled_trials.pdfAccessed February 25, 2013
   Google Scholar
• CaldwellDMAdesAEHigginsJPSimultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• JansenJPCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisonsValue Health200811595696418489499
   PubMed Web of Science ®Google Scholar
• DempsterAPThe direct use of likelihood for significance testingStatistics and Computing199774247252
   Web of Science ®Google Scholar
• SpiegelhalterDJBestNGCarlinBPVan Der LindeABayesian measures of model complexity and fitJ R Stat Soc Series B Stat Methodol2002644583639
   Web of Science ®Google Scholar
• DiasSWeltonNJSuttonAJAdesAENICE DSU Technical Support Document 2: A generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials Available from: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%20Mar2013.pdfAccessed October 9, 2012
   Google Scholar
• CopeSZhangJWilliamsJJansenJPEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisBMC Pulm Med2012122922732017
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• CooperNJSuttonAJMorrisDAdesAEWeltonNJAddressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillationStat Med200928141861188119399825
   PubMed Web of Science ®Google Scholar
• LunnDJThomasABestNSpiegelhalterDWinBUGs – A Bayesian modelling framework: Concepts, structure, and extensibilityStatistics and Computing2000104325337
   Web of Science ®Google Scholar
• Forest Research Institute, IncClinical Study Report LAS-MD-33: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs Placebo When Administered to Patients with Moderate to Severe Chronic Obstructive Pulmonary DiseaseClinical Trial Registry [NCT0891462] Available from: http://clinicaltrials.gov/ct2/show/NCT0891462
   Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarciaGECaractaCFACCORD I study investigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• Forest Research Institute, IncClinical Study Report LAS-MD-38: A Randomized, Double Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients with Moderate to Severe Stable Chronic Obtructive Pulmonary Disease Followed by a 40-week Evaluation of the Higher Bromide DoseClinical Trial Registry [NCT1045161] Available from: http://clinicaltrials.gov/ct2/show/NCT1045161
   Google Scholar
• AlmirallSAClinical Study Report LAS-MD-34: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Clinical Trial Registry [NCT1001494] Available from: http://clinicaltrials.gov/show/NCT1001494
   Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. [Erratum appears in Thorax. Feb 2005;60(2):105]Thorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDJrDonohueJFSerbyCWMenjogeSSWitekTJJrThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study GroupChest200011851294130211083677
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• ChanCKMaltaisFSigouinCHaddonJMFordGTSAFE Study GroupA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J200714846547218060091
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy200525121708171816305289
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJINHANCE Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• MoitaJBárbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther200821114615117693107
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med2005143531732616144890
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• TonnelABPerezTGrosboisJMVerkindreCBravoMLBrunMTIPHON study groupEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J Chron Obstruct Pulmon Dis20083230131018686739
   PubMedGoogle Scholar
• VerkindreCBartFAguilaniuBThe effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration200673442042716484769
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• VoshaarTLapidusRMaleki-YazdiRA randomized study of tiotropium Respimat Soft Mist inhaler vs ipratropium pMDI in COPDRespir Med20081021324117996436
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• van der MolenTCazzolaMBeyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrim Care Respir J201221110110822222945
   PubMedGoogle Scholar
• KarabisALindnerLMocarskiMComparative efficacy of aclidinium bromide 400 Mcg bid versus tiotropium 18 Mcg and 5 Mcg QD as maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): a network meta-analysisValue Health2012157A560
   Web of Science ®Google Scholar
• YohannesAMWillgossTGVestboJTiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Res2011564477487
   Google Scholar